scholarly journals Bronchial Washing Fluid Versus Plasma and Bronchoscopy Biopsy Samples for Detecting Epidermal Growth Factor Receptor Mutation Status in Lung Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Xinyu Zhang ◽  
Chun Li ◽  
Maosong Ye ◽  
Qin Hu ◽  
Jie Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Egfr Mutation ◽  
Growth Factor Receptor ◽  
Mutation Testing ◽  
Plasma Samples ◽  
Mutation Status ◽  
Bronchial Washing ◽  
Epidermal Growth ◽  
Egfr Mutation Testing

BackgroundBronchial washing fluid (BWF) is a common specimen collected during bronchoscopy and has been suggested to contain both tumor cells and cell-free DNA. However, there is no consensus on the feasibility of BWF in epidermal growth factor receptor (EGFR) genetic analysis because of the limited sample size and varying results in previous studies. This study compared the feasibility, sensitivity, and specificity of detecting EGFR mutation using BWF, bronchoscopy biopsy, and plasma samples in patients with lung cancer (LC).Materials and MethodsA total of 144 patients (110 with LC and 34 without LC) were enrolled in the study. During diagnostic bronchoscopy for suspected LC lesions, bronchial washing with saline was performed directly or through a guide sheath. BWF was collected as well as paired bronchoscopy biopsy and plasma samples, and EGFR mutation testing was performed via highly sensitive blocker polymerase chain reaction. The EGFR mutation status of histologic samples was set as the standard reference.ResultsCompared with the histologic samples, the sensitivity, specificity, and concordance rate of EGFR mutation detected in BWF samples were 92.5%, 100%, and 97.9%, respectively. Moreover, BWF showed a higher sensitivity in EGFR mutation testing than both plasma (100% [8/8] vs. 62.5% [5/8], p = 0.095) and bronchoscopy biopsy samples (92.5% [37/40] vs. 77.5% [31/40], p = 0.012) and identified EGFR mutations in 6 cases whose biopsy failed to establish an LC diagnosis. The diameter of the target lesion and its contact degree with BWF were positive predictive factors for EGFR testing results.ConclusionsBWF yields a high sensitivity in EGFR mutation testing, having high concordance with histologic samples, and presenting the benefit of rapid EGFR mutation detection in LC patients.

A comparison of bronchofiberscopic (BFS) washing cytology (BWC) and formalin-fixed paraffin-embedded tissue (PPFE) in the analysis of EGFR mutations in advanced non-small cell lung cancer (NSCLC).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 8054-8054
Author(s):  
Naoya Hida ◽  
Yuuki Misumi ◽  
Yoko Agemi ◽  
Akira Sato ◽  
Mari Ishii ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Egfr Mutation ◽  
High Reliability ◽  
High Sensitivity ◽  
Mutation Testing ◽  
Egfr Mutations ◽  
Mutation Site ◽  
Mutation Status ◽  
Bronchial Washing ◽  
Egfr Mutation Testing

8054 Background: In the treatment of advanced NSCLC, EGFR mutation status is one of the most predictive factors for the efficacy of EGFR tyrosine kinase inhibitors, and the evaluation of EGFR mutation status using the PPFE has been widely used for this analysis throughout the world. However, whether BWC can be used as an alternative for PPFE in the analysis of EGFR mutations is unknown. The largest study evaluating these 2 methods included only around 20 samples. Therefore, in the current study, we compared the freeze stock solution of BWC with PPFE for the determination of EGFR mutation status in a large sample set. Methods: In diagnostic BFS examinations, after curetting or brushing and biopsy to target lesions, subsequent bronchial washing by saline was performed. Thereafter, the saline fluid in which the forceps were washed and the bronchial washing fluid were mixed in a sterilized tube and were immediately frozen in a -20°C freezer. EGFR mutation testing for both BWC and PPFE was performed using high-sensitivity PCR (BML, PCR-Invader). Results: A total of 440 BFS examinations were performed from Aug 2010 to Nov 2011 in our hospital. The BWCs of 268 suspected cases of lung cancer were successfully obtained. Of these, 51 cases that were pathologically confirmed as adenocarcinoma based on both BWC and PPFE were analyzed in this study. EGFR mutations were identified in 25 cases, while the remaining 26 cases had wild-type EGFR. In 49 of 51 cases, the results of EGFR mutation status were the same for BWC and PPFE, and the concordance rate was 96%. In one case, an exon-18 mutation was detected only by BWC. In another case an exon-21 mutation was detected only by PPFE. In 24 of 25 cases of EGFR mutation, the mutation site was the same in both samples. The kappa coefficient was 0.92. Conclusions: This is the largest genetic study to date demonstrating a head-to-head comparison of BWC and PPFE for the evaluation of EGFR mutations. Both methods showed high reliability and concordance using high-sensitivity PCR. BWC is considered a simple, rapid method and represents an effective alternative for PPFE in EGFR mutation testing.

scholarly journals Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Rhian Siân Davies ◽  
Christian Smith ◽  
Gwenllian Edwards ◽  
Rachel Butler ◽  
Diane Parry ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Growth Factor Receptor ◽  
Genetic Alterations ◽  
Mutation Testing ◽  
Sample Collection ◽  
Single Institution ◽  
Mutation Status ◽  
Tumour Sample ◽  
Epidermal Growth ◽  
Egfr Mutation Testing

Objectives. There have been advances in the identification and understanding of molecular subsets of lung cancer, defined by specific oncogenic aberrations. A number of actionable genetic alterations have been identified, such as the epidermal growth factor receptor (EGFR) mutation. We aimed to establish the reasons why patients were not undergoing EGFR mutation testing at the time of histological diagnosis. Methods. The records of 70 patients with advanced adenocarcinoma of the lung managed through a single multidisciplinary team at a single institution were reviewed. Data were collected on method of tumour sample collection, whether this was sent for EGFR testing, and the result. Results. Seventy patients were identified. In 21/25 (84%) cases, cytological sampling was sufficient for EGFR mutation analysis, compared with 40/45 (89%) cases with histological sampling. EGFR mutation testing was not carried out in 22/70 (31.4%) patients. There was insufficient tumour sample for EGFR testing in 9/22 (40.9%) patients. Other reasons for not testing included poor patient fitness and problems in the diagnostic pathway. Conclusions. In this series, cytological tumour sampling was not the predominant reason why cancers failed to have EGFR mutation status established.

scholarly journals Pre- and post-surgery change of EGFR mutation status in a lung squamous cell cancer patient

2021 ◽  
Author(s):  
Mingming Hu ◽  
Fugen Li ◽  
Yun Zhao ◽  
Baohua Lu ◽  
Haifeng Lin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Peripheral Blood ◽  
Egfr Mutation ◽  
Growth Factor Receptor ◽  
Surgical Operation ◽  
Mutation Status ◽  
Squamous Lung Cancer ◽  
Epidermal Growth

Abstract BackgroundThe percentage of epidermal growth factor receptor (EGFR) mutations in squamous lung cancer was relatively low. The dynamic changes of EGFR mutation in peripheral blood before and after surgical resection in epidermal growth factor receptor (EGFR) has been rarely reported.Case presentationWe report a 73-year-old woman with squamous lung cancer of the left upper lobe and EGFR exon 19 deletion (19del) was identified in biopsy and peripheral plasma separately before a surgical operation. The mass regressed remarkably after three cycles of platinum-based neoadjuvant chemotherapy and then the patient was administered curative-intent surgery. Postoperative pathology supported the diagnosis of left upper lobe squamous cell carcinoma and EGFR 19del mutation. At the time of 40 days after surgery, EGFR 19del mutation in peripheral blood was undetectable using amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) and next-generation sequencing (NGS) method.ConclusionsWe report, for the first time, the perioperational dynamics of EGFR mutation in a LSCC patient. EGFR 19del mutation was eliminated after surgical operation. The genetic mutation status from peripheral blood could be converted through the operation.

Tailored treatment with targeted therapies in non-small cell lung cancer (NSCLC) based on the epidermal growth factor receptor gene (EGFR) mutation testing.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e19150-e19150
Author(s):  
Saray Galvan Ruiz ◽  
Maria Hernandez Sosa ◽  
Samuel Hernandez Sarmiento ◽  
Marta Mori de Santiago ◽  
Maria Jesus Blanco Sánchez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Egfr Mutation ◽  
Receptor Gene ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tailored Treatment ◽  
Epidermal Growth ◽  
Egfr Mutation Testing
Sign in / Sign up

Export Citation Format

Share Document